journal article·2026-02-04

Complement C1q-Targeted Microglial Membrane Camouflaged Nanolipid Carriers for Synaptic Protection in Alzheimer’s Disease: A Bioinspired Alectinib Delivery Strategy

Ya-Ning Ding, Mei-Qi Li, Ping-Tian Ding, Pu Wang, Pei-Pei Guan

Nano Letters· Volume 26· Issue 4
Publisher page

Abstract

Aberrant activation of the complement system drives early synaptic loss and chronic neuroinflammation in Alzheimer's disease (AD). Here, we identified complement component C1q as a key upregulated target in AD and screened Alectinib (ALE), an FDA-approved kinase inhibitor, as a high-affinity C1q binder. To achieve brain-targeted delivery, ALE was encapsulated in nanostructured lipid carriers camouflaged with microglial membranes (ALE@MM-NLCs). This biomimetic design enhanced blood-brain barrier (BBB) penetration and microglial uptake. In APP/PS1 mice, ALE@MM-NLCs improved cognitive performance and reduced C1q expression, β-amyloid (Aβ) burden, and glial activation, while promoting microglial M2-like polarization. Mechanistically, ALE@MM-NLCs suppressed oxidative stress, NLRP3 inflammasome activation, and C1q-mediated synaptosome phagocytosis, thereby preventing proteasome-dependent synaptic degradation. These results highlight ALE@MM-NLCs as a promising immunomodulatory nanotherapy for synaptic preservation and early AD intervention.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Neuroinflammation and Neurodegeneration Mechanisms · Alzheimer's disease research and treatments · Tryptophan and brain disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Life and Health Sciences

Northeastern University

College of Pharmacy

Shenzhen Technology University

Funding

Shenzhen Technology University · Department of Education of Liaoning Province · Shenzhen Medical Research Fund

References (34)

Show source-provided references
1. 10.1016/j.neuron.2021.11.00810.1016/j.neuron.2021.11.008 ↗
2. 10.1126/science.aad837310.1126/science.aad8373 ↗
3. 10.3233/JAD-12193010.3233/JAD-121930 ↗
4. 10.1016/j.imbio.2011.07.01710.1016/j.imbio.2011.07.017 ↗
5. 10.1038/s43587-022-00281-110.1038/s43587-022-00281-1 ↗
6. 10.1016/j.ajpath.2011.01.00610.1016/j.ajpath.2011.01.006 ↗
7. 10.1002/eji.20235081510.1002/eji.202350815 ↗
8. 10.1007/7854_2024_52410.1007/7854_2024_524 ↗
9. 10.1186/s12974-023-02850-610.1186/s12974-023-02850-6 ↗
10. 10.1016/j.neuron.2018.10.03110.1016/j.neuron.2018.10.031 ↗
11. 10.1002/alz.1427110.1002/alz.14271 ↗
12. 10.1016/j.dadm.2018.11.00210.1016/j.dadm.2018.11.002 ↗
13. 10.1016/j.neubiorev.2024.10586810.1016/j.neubiorev.2024.105868 ↗
14. 10.1093/brain/awae27810.1093/brain/awae278 ↗
15. 10.1177/1387287725132280810.1177/13872877251322808 ↗
16. 10.1007/s00406-021-01273-910.1007/s00406-021-01273-9 ↗
17. 10.1038/s41380-019-0536-810.1038/s41380-019-0536-8 ↗
18. 10.3390/genes1203044310.3390/genes12030443 ↗
19. 10.1186/s13578-024-01223-710.1186/s13578-024-01223-7 ↗
20. 10.1038/s41467-024-52173-010.1038/s41467-024-52173-0 ↗
21. 10.3390/brainsci1405043410.3390/brainsci14050434 ↗
22. 10.1038/s41467-018-06118-z10.1038/s41467-018-06118-z ↗
23. 10.1016/j.immuni.2018.04.01610.1016/j.immuni.2018.04.016 ↗
24. 10.1186/s12974-023-02885-910.1186/s12974-023-02885-9 ↗
25. 10.1074/jbc.M112.40016810.1074/jbc.M112.400168 ↗
26. 10.1523/JNEUROSCI.0901-04.200410.1523/JNEUROSCI.0901-04.2004 ↗
27. 10.1016/S0165-5728(02)00444-710.1016/S0165-5728(02)00444-7 ↗
28. 10.2478/prilozi-2020-003010.2478/prilozi-2020-0030 ↗
29. 10.1016/j.virol.2014.02.00710.1016/j.virol.2014.02.007 ↗
30. 10.1186/1742-2094-9-19310.1186/1742-2094-9-193 ↗
31. 10.1021/acs.molpharmaceut.6b0039710.1021/acs.molpharmaceut.6b00397 ↗
32. 10.1038/nn199710.1038/nn1997 ↗
33. 10.1038/nrendo.2015.4810.1038/nrendo.2015.48 ↗
34. 10.1126/science.107406910.1126/science.1074069 ↗